News

The Pasteur Institute in Ho Chi Minh City and Nagasaki University of Japan, both leading facilities in tropical medicine and ...
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...
Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...
In 2024, Sanofi’s Vaccines segment recorded sales growth of 13.5% at a constant exchange rate, exceeding management’s expectations. Sanofi continues to expand its vaccine business further.